A Phase 2/3 interventional study of Atacicept and Mycophenolate mofetil in Lupus Nephritis, sponsored by EMD Serono. Terminated at 20 sites in 5 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2016-03-23.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.
Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 83rd largest by enrollment of the 100 interventional ones that give a count, is one of 2 that started in 2007, is the only one in phase 2/3, and was the 12th registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
iCell Gene Therapeutics · Sites in United States
Ages 16–70
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 47 · Phase 3 17 · Phase 4 7
First in 1994; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 50 across the 100 interventional studies, 265 across the 14 observational. Of the 53 that completed or were terminated, 31 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 114 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 2 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
11 of the studies in Lupus Nephritis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT06518668Hospital for Special Surgery, New YorkA Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | 2026-12 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06217107Morehouse School of MedicineWellness & Workforce Solution for Lupus/Lupus Nephritis | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 114 studies in Lupus Nephritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn whether atacicept treatment leads to improvement in kidney function in subjects with active lupus nephritis in combination with mycophenolate mofetil (MMF) and corticosteroids. The study was sponsored by Merck Serono International; operational oversight was provided by ZymoGenetics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Atacicept · Drug: Mycophenolate mofetil · Drug: Corticosteroids
Drug: Mycophenolate mofetil · Drug: Placebo · Drug: Corticosteroids
Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
Percentage of Participants With Confirmed Complete Renal Response (CRR), Partial Response, and Non-response
Complete renal response (CRR): from baseline, a return to within 10% of normal for renal function (assessed by calculated glomerular filtration rate \[GFR\]), improvement in proteinuria (urine protein/creatinine ratio \<0.5) \& resolution of hematuria. Partial response (PR): from baseline, a \<= 10% worsening in renal function ( by calculated GFR); 50% improvement in proteinuria (assessed by urine protein/creatinine ratio) \& resolution of hematuria, Non-response (NR): Neither criteria for CR or PR was met. Subjects were also deemed NR if they had treatment failure, regardless of CR or PR status. Subjects cannot be treatment failures. A response of CRR was confirmed if the Week 52 value is CRRand if the Week 48 value is CRR and at least 4 weeks apart from Week 52 /if the Week 48 value was missing/ less than 4 weeks from Week 52, then the Week 56 response must be CRR - if the Week 52 value was missing, then Week 48 and Week 56 must be CRR.
Time frame: At Week 52
Percentage of Participants With Normalization of Renal Function
Time frame: At Week 52
Number of Participants With New Lupus Flares
Time frame: At Week 52
| Milestone | Atacicept Plus Mycophenolate Mofetil Plus Corticosteroids | Placebo Plus Mycophenolate Mofetil Plus Corticosteroids |
|---|---|---|
| Started | 4 | 2 |
| Completed | 0 | 0 |
| Not completed | 4 | 2 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Other | 1 | 1 |
Complete renal response (CRR): from baseline, a return to within 10% of normal for renal function (assessed by calculated glomerular filtration rate \[GFR\]), improvement in proteinuria (urine protein/creatinine ratio \<0.5) \& resolution of hematuria. Partial response (PR): from baseline, a \<= 10% worsening in renal function ( by calculated GFR); 50% improvement in proteinuria (assessed by urine protein/creatinine ratio) \& resolution of hematuria, Non-response (NR): Neither criteria for CR or PR was met. Subjects were also deemed NR if they had treatment failure, regardless of CR or PR status. Subjects cannot be treatment failures. A response of CRR was confirmed if the Week 52 value is CRRand if the Week 48 value is CRR and at least 4 weeks apart from Week 52 /if the Week 48 value was missing/ less than 4 weeks from Week 52, then the Week 56 response must be CRR - if the Week 52 value was missing, then Week 48 and Week 56 must be CRR.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over From the first dose of trial medication to 24-Week follow-up after last dose of trial medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atacicept Plus Mycophenolate Mofetil Plus Corticosteroids | — | 3/4 (75%) | 4/4 (100%) |
| Placebo Plus Mycophenolate Mofetil Plus Corticosteroids | — | 0/2 (0%) | 1/2 (50%) |
| Event | Atacicept Plus Mycophenolate Mofetil Plus Corticosteroids | Placebo Plus Mycophenolate Mofetil Plus Corticosteroids |
|---|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/4 | 0/2 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/4 | 0/2 |
| SyncopeNervous system disorders | 1/4 | 0/2 |
| AnaemiaBlood and lymphatic system disorders | 1/4 | 0/2 |
| EmpyemaInfections and infestations | 1/4 | 0/2 |
| PneumoniaInfections and infestations | 1/4 | 0/2 |
| Pneumonia legionellaInfections and infestations | 1/4 | 0/2 |
| SepsisInfections and infestations | 1/4 | 0/2 |
| Renal failure acuteRenal and urinary disorders | 1/4 | 0/2 |
| Hypertensive crisisVascular disorders | 1/4 | 0/2 |
| Event | Atacicept Plus Mycophenolate Mofetil Plus Corticosteroids | Placebo Plus Mycophenolate Mofetil Plus Corticosteroids |
|---|---|---|
| NauseaGastrointestinal disorders | 1/4 | 1/2 |
| Abdominal painGastrointestinal disorders | 0/4 | 1/2 |
| Injection site haematomaGeneral disorders | 0/4 | 1/2 |
| HypokalaemiaMetabolism and nutrition disorders | 2/4 | 0/2 |
| TachycardiaCardiac disorders | 1/4 | 1/2 |
| PalpitationsCardiac disorders | 0/4 | 1/2 |
| HypogammaglobulinaemiaImmune system disorders | 2/4 | 0/2 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/4 | 1/2 |
| DysgeusiaNervous system disorders | 0/4 | 1/2 |
| Leukocytoclastic vasculitisSkin and subcutaneous tissue disorders | 0/4 | 1/2 |
Baseline analysis population included all the participants randomized in the trial.
| Age, Continuous(years) | Atacicept Plus Mycophenolate Mofetil Plus Corticosteroids | Placebo Plus Mycophenolate Mofetil Plus Corticosteroids | Total |
|---|---|---|---|
| Mean | 36.8 ± 11.3 | 36.0 ± 25.5 | 36.5 ± 14.4 |
| Sex: Female, Male(Participants) | Atacicept Plus Mycophenolate Mofetil Plus Corticosteroids | Placebo Plus Mycophenolate Mofetil Plus Corticosteroids | Total |
|---|---|---|---|
| Female | 3 | 1 | 4 |
| Male | 1 | 1 | 2 |
The record gives a start of Dec 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 6 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein